Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

1.

Development of Sanofi Pasteur tetravalent dengue vaccine.

Guy B, Saville M, Lang J.

Hum Vaccin. 2010 Sep 16;6(9). doi: 10.4161.hv.6.9.12739. Epub 2010 Sep 16.

PMID:
20861669
[PubMed]
Free Article
2.

Recent progress on sanofi pasteur's dengue vaccine candidate.

Lang J.

J Clin Virol. 2009 Oct;46 Suppl 2:S20-4. doi: 10.1016/S1386-6532(09)70291-4.

PMID:
19800562
[PubMed - indexed for MEDLINE]
3.

From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Guy B, Barrere B, Malinowski C, Saville M, Teyssou R, Lang J.

Vaccine. 2011 Sep 23;29(42):7229-41. doi: 10.1016/j.vaccine.2011.06.094. Epub 2011 Jul 13. Review.

PMID:
21745521
[PubMed - indexed for MEDLINE]
4.

Immunogenicity of sanofi pasteur tetravalent dengue vaccine.

Guy B.

J Clin Virol. 2009 Oct;46 Suppl 2:S16-9. doi: 10.1016/S1386-6532(09)70290-2.

PMID:
19800561
[PubMed - indexed for MEDLINE]
5.

Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study.

Osorio JE, Velez ID, Thomson C, Lopez L, Jimenez A, Haller AA, Silengo S, Scott J, Boroughs KL, Stovall JL, Luy BE, Arguello J, Beatty ME, Santangelo J, Gordon GS, Huang CY, Stinchcomb DT.

Lancet Infect Dis. 2014 Sep;14(9):830-8. doi: 10.1016/S1473-3099(14)70811-4. Epub 2014 Jul 23.

PMID:
25087476
[PubMed - in process]
6.

[Dengue fever: from disease to vaccination].

Teyssou R.

Med Trop (Mars). 2009 Aug;69(4):333-4. French.

PMID:
19725380
[PubMed - indexed for MEDLINE]
7.

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.

Guy B, Nougarede N, Begue S, Sanchez V, Souag N, Carre M, Chambonneau L, Morrisson DN, Shaw D, Qiao M, Dumas R, Lang J, Forrat R.

Vaccine. 2008 Oct 23;26(45):5712-21. doi: 10.1016/j.vaccine.2008.08.019. Epub 2008 Aug 30.

PMID:
18762226
[PubMed - indexed for MEDLINE]
8.

Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.

Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, Forrat R, Wartel A, Crevat D.

Vaccine. 2011 May 17;29(22):3863-72. doi: 10.1016/j.vaccine.2011.03.057. Epub 2011 Apr 6.

PMID:
21477675
[PubMed - indexed for MEDLINE]
9.

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

Guirakhoo F, Kitchener S, Morrison D, Forrat R, McCarthy K, Nichols R, Yoksan S, Duan X, Ermak TH, Kanesa-Thasan N, Bedford P, Lang J, Quentin-Millet MJ, Monath TP.

Hum Vaccin. 2006 Mar-Apr;2(2):60-7. Epub 2006 Mar 15.

PMID:
17012873
[PubMed - indexed for MEDLINE]
Free Article
10.

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.

Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, Saluzzo JF, Bhamarapravati N.

Pediatr Infect Dis J. 2004 Feb;23(2):99-109.

PMID:
14872173
[PubMed - indexed for MEDLINE]
11.

Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.

Poo J, Galan F, Forrat R, Zambrano B, Lang J, Dayan GH.

Pediatr Infect Dis J. 2010 Oct 29. [Epub ahead of print]

PMID:
21042231
[PubMed - as supplied by publisher]
12.

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates.

Guirakhoo F, Pugachev K, Zhang Z, Myers G, Levenbook I, Draper K, Lang J, Ocran S, Mitchell F, Parsons M, Brown N, Brandler S, Fournier C, Barrere B, Rizvi F, Travassos A, Nichols R, Trent D, Monath T.

J Virol. 2004 May;78(9):4761-75.

PMID:
15078958
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine.

Guirakhoo F, Arroyo J, Pugachev KV, Miller C, Zhang ZX, Weltzin R, Georgakopoulos K, Catalan J, Ocran S, Soike K, Ratterree M, Monath TP.

J Virol. 2001 Aug;75(16):7290-304.

PMID:
11462001
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.

Lanata CF, Andrade T, Gil AI, Terrones C, Valladolid O, Zambrano B, Saville M, Crevat D.

Vaccine. 2012 Sep 7;30(41):5935-41. doi: 10.1016/j.vaccine.2012.07.043. Epub 2012 Jul 31.

PMID:
22863660
[PubMed - indexed for MEDLINE]
16.

Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.

Dayan GH, Thakur M, Boaz M, Johnson C.

Vaccine. 2013 Oct 17;31(44):5047-54. doi: 10.1016/j.vaccine.2013.08.088. Epub 2013 Sep 7.

PMID:
24021313
[PubMed - indexed for MEDLINE]
17.

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers.

Kanesa-thasan N, Sun W, Kim-Ahn G, Van Albert S, Putnak JR, King A, Raengsakulsrach B, Christ-Schmidt H, Gilson K, Zahradnik JM, Vaughn DW, Innis BL, Saluzzo JF, Hoke CH Jr.

Vaccine. 2001 Apr 30;19(23-24):3179-88.

PMID:
11312014
[PubMed - indexed for MEDLINE]
18.

Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.

Villar LÁ, Rivera-Medina DM, Arredondo-García JL, Boaz M, Starr-Spires L, Thakur M, Zambrano B, Miranda MC, Rivas E, Dayan GH.

Pediatr Infect Dis J. 2013 Oct;32(10):1102-9. doi: 10.1097/INF.0b013e31829b8022.

PMID:
24067553
[PubMed - indexed for MEDLINE]
19.

Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections.

Monath TP, McCarthy K, Bedford P, Johnson CT, Nichols R, Yoksan S, Marchesani R, Knauber M, Wells KH, Arroyo J, Guirakhoo F.

Vaccine. 2002 Jan 15;20(7-8):1004-18.

PMID:
11803060
[PubMed - indexed for MEDLINE]
20.

Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, Lang J.

Vaccine. 2010 Jan 8;28(3):632-49. doi: 10.1016/j.vaccine.2009.09.098. Epub 2009 Oct 4. Review.

PMID:
19808029
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk